Apimeds Pharmaceuticals US, Inc.

As of June 30, 2026, Apimeds Pharmaceuticals US, Inc. carries a market capitalization of 13.58M, placing it among publicly traded companies globally. Its enterprise value stands at 27.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Apimeds Pharmaceuticals US, Inc. has 1.51M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Apimeds Pharmaceuticals US, Inc. maintains a current ratio of 0.51, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.69, indicating elevated leverage, while an interest coverage ratio of -6.34 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Apimeds Pharmaceuticals US, Inc. posted a negative return on equity (ROE) of -100.13, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -84.20, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 5.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Apimeds Pharmaceuticals US, Inc.'s stock has declined approximately 98.24% over the past 52 weeks. The 50-day moving average sits at 3.86, while the 200-day moving average is 67.64.

Over the twelve months ended June 30, 2026, Apimeds Pharmaceuticals US, Inc. generated - - in revenue and converted that into -58.17M in net income, yielding earnings per share of -40.26. EBITDA reached -27.30M, while operating income came in at -27.35M.

As of June 30, 2026, Apimeds Pharmaceuticals US, Inc. holds 278,371.00 in cash and equivalents against 14.57M in total debt, resulting in a net debt position of 14.13M. Total book value stands at 106.45M, with working capital of -10.39M providing operational flexibility.

Apimeds Pharmaceuticals US, Inc. produced -13.28M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -53,358.00 in capital expenditures, free cash flow totaled -13.33M - equivalent to -9.23 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -102.52: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -94.82, meaning Apimeds Pharmaceuticals US, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Apimeds Pharmaceuticals US, Inc.'s most recent stock split took place on July 24, 2026 with a 10:1 split ratio.

As of June 30, 2026, Apimeds Pharmaceuticals US, Inc. has an Altman Z-Score of -1.14, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.